Initial Medication for Suicidal Patients with Heavy Alcohol Use

Medication Selection

The American Academy of Child and Adolescent Psychiatry recommends avoiding tricyclic antidepressants in suicidal patients with substance use due to their high lethality in overdose, with a fatal toxicity index 5-8 times higher than SSRIs 1, 2, 3
The American College of Physicians suggests that sertraline 50mg once daily is the preferred initial choice for patients with suicidal ideation and heavy drinking, due to its dramatically lower fatal toxicity index (0.5) compared to tricyclics (13.8) 1, 2
The American Psychiatric Association recommends fluoxetine 20mg once daily as an equally strong alternative, which can be started closer to full therapeutic dose than other SSRIs, providing more rapid onset 1

The Journal of the American Academy of Child and Adolescent Psychiatry advises against prescribing venlafaxine (SNRI) in suicidal patients with substance use, as it is associated with greater suicide risk than other antidepressants and overdose fatalities 3
The American College of Physicians warns against prescribing benzodiazepines in suicidal patients with substance use, as they may reduce self-control and disinhibit suicidal behavior, potentially precipitating suicide attempts 1, 2

The American Medical Association recommends that all medication be controlled by a third party (family member/trusted person) who dispenses daily doses only, stores all medications securely, and reports any unexpected mood changes or side effects 1, 4
The National Institute of Mental Health suggests systematically inquiring about suicidal ideation before and after starting medication, and watching for behavioral activation/agitation, which may require dose reduction 1, 2

The American Psychiatric Association recommends ketamine infusion (0.5 mg/kg IV) for rapid reduction in suicidal ideation within 24 hours, with effects lasting up to 1 week, bridging the gap until antidepressant reaches therapeutic levels 1
The American College of Physicians suggests adding lithium or valproate as primary mood stabilizer with anti-suicidal properties if bipolar features emerge during treatment, and continuing SSRI as adjunctive therapy 1